Renal cortical retention on delayed CT and nephropathy following transcatheter arterial chemoembolisation.

The aim of this study was to examine the relationship between renal cortical retention on delayed CT and contrast medium-associated and/or transarterial chemoembolisation (TACE)-associated nephropathy following TACE. The authors reviewed the findings on 180 treatments in 121 patients with normal serum creatinine levels who underwent TACE for liver tumours. Nephropathy was defined as an increase in the creatinine level of greater than 0.5 mg x dl(-1) (44 micromol x l(-1)) and greater than 25% on days 1, 3, 7 or 14 post TACE. Renal cortical retention was recognized when CT values for the renal cortex showed either mild renal cortical retention (CT value >50) or severe renal cortical retention (CT value >100). There was evidence of renal cortical retention in 81 (45%) cases and of nephropathy in 11 (6%) cases. Only 2% of patients without renal cortical retention showed nephropathy, whereas 11% of those with renal cortical retention showed nephropathy (p=0.02). Stepwise selection using a multivariate logistic regression model showed renal cortical retention and gender to be significant factors for nephropathy following TACE. In conclusion, renal cortical retention is a useful predicator for nephropathy following TACE. Delayed CT could be used not only for assessment of lipiodol retention but also for predicting nephropathy.

[1]  D. Oliveira.  Prophylaxis against contrast-induced nephropathy , 1999, The Lancet.

[2]  W. O’Neill,et al.  A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy ☆: Results of the P.R.I.N.C.E. study , 1999 .

[3]  R. Solomon,et al.  Contrast-medium-induced acute renal failure. , 1998, Kidney international.

[4]  T. Nose,et al.  Renal cortical retention on delayed CT after angiography and contrast associated nephropathy. , 1997, The British journal of radiology.

[5]  J. Jakobsen,et al.  Delayed CT of the kidneys after iopentol (Imagopaque® 350) injection in patients with normal renal function An assessment of the gradual decrease in opacification over 32 h after injection , 1997, European Radiology.

[6]  T. Higashi,et al.  Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma. , 1997, Digestion.

[7]  J. Ellis,et al.  Assessment of renal function with computed tomographic densitometry measurements. , 1996, Academic radiology.

[8]  T. Nose,et al.  Renal cortical retention of contrast medium after angiography as assessed by delayed CT: a multivariate analysis. , 1996, Radiation medicine.

[9]  M. Shimada,et al.  Renal function after elective hepatic resection. , 1996, Hepato-gastroenterology.

[10]  K. Rootwelt,et al.  Angiography with nonionic X-ray contrast media in severe chronic renal failure: renal function and contrast retention. , 1996, Nephron.

[11]  Y. Nose,et al.  Estimation of risk of major complications after hepatic resection. , 1994, American journal of surgery.

[12]  P. Kurnik,et al.  Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. , 1994, Kidney international.

[13]  A. Peters,et al.  The use of contrast-enhanced CT for the study of renal function and physiology , 1993 .

[14]  M. Ychou,et al.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors a prospective phase II study in 24 patients , 1993, Cancer.

[15]  D. Allison,et al.  THERAPEUTIC EMBOLISATION OF THE HEPATIC ARTERY: A REVIEW OF 75 PROCEDURES , 1985, The Lancet.

[16]  W. F. Mason,et al.  Therapeutic embolization of the hepatic artery. , 1985, Journal of the Canadian Association of Radiologists.

[17]  M. Korobkin,et al.  Contrast-induced acute renal failure: persistent nephrogram as clue to early detection. , 1980, AJR. American journal of roentgenology.